RxSight (RXST) Cost of Revenue (2020 - 2025)
RxSight (RXST) has disclosed Cost of Revenue for 6 consecutive years, with $7.3 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Cost of Revenue fell 35.73% year-over-year to $7.3 million, compared with a TTM value of $31.5 million through Dec 2025, down 23.21%, and an annual FY2025 reading of $31.5 million, down 23.21% over the prior year.
- Cost of Revenue was $7.3 million for Q4 2025 at RxSight, up from $6.1 million in the prior quarter.
- Across five years, Cost of Revenue topped out at $11.4 million in Q4 2024 and bottomed at $2.4 million in Q1 2021.
- Average Cost of Revenue over 5 years is $7.7 million, with a median of $7.9 million recorded in 2025.
- The sharpest move saw Cost of Revenue surged 119.07% in 2022, then tumbled 39.44% in 2025.
- Year by year, Cost of Revenue stood at $5.6 million in 2021, then skyrocketed by 55.95% to $8.7 million in 2022, then rose by 26.08% to $10.9 million in 2023, then increased by 4.58% to $11.4 million in 2024, then plummeted by 35.73% to $7.3 million in 2025.
- Business Quant data shows Cost of Revenue for RXST at $7.3 million in Q4 2025, $6.1 million in Q3 2025, and $8.4 million in Q2 2025.